NCT01039675View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 1, 2010

Primary Completion Date

April 1, 2010

Study Completion Date

April 20, 2010

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

500mcg/25mcg once daily

GSK573719/GW642444

DRUG

Placebo once daily

Inactive, excipients only

Trial Locations (4)

29340

GSK Investigational Site, Gaffney

29615

GSK Investigational Site, Greenville

29646

GSK Investigational Site, Greenwood

29706

GSK Investigational Site, Chester

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY